Literature DB >> 41661

Role of the lung in total body clearance of circulating drugs.

R A Roth, D A Wiersma.   

Abstract

Attention in recent years has focused upon the ability of lung to accumulate and/or to metabolise circulating hormones, drugs and other xenobiotic agents. Although often studied in broken cell preparations, such functions must be examined in intact lung before extrapolation to the situation in vivo is possible. The role of lung in total body clearance of xenobiotic agents is often considered to be small, as compared with the liver it usually has much lower concentrations of degradative enzymes and a smaller mass. However, consideration of such factors as organ blood flow or stimulation of drug metabolising enzymes suggests that the contribution of the lung to total body clearance of some drugs is greater than previously recognised. This may explain some of the alterations in drug clearance seen clinically. For example, cigarette smoking may increase the clearance of certain xenobiotic compounds by stimulating pulmonary drug metabolising enzymes. Pulmonary drug disposition may also be altered by conditions affecting cardiac output, such as exercise, hypoxia, and circulatory shock, or those affecting acid-base balance, such as hyperventilation. In addition, pneumotoxicants may affect pulmonary clearance of circulating drugs and xenobiotics.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41661     DOI: 10.2165/00003088-197904050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  95 in total

1.  Liver blood flow and blood volume following chronic phenobarbitone administration.

Authors:  E E Ohnhaus; J T Locher
Journal:  Eur J Pharmacol       Date:  1975-04       Impact factor: 4.432

2.  METABOLISM OF VASOMOTOR AGENTS BY THE ISOLATED PERFUSED LUNG.

Authors:  B EISEMAN; L BRYANT; T WALTUCH
Journal:  J Thorac Cardiovasc Surg       Date:  1964-11       Impact factor: 5.209

3.  5-Hydroxytryptamine; pharmacological action and destruction in perfused lungs.

Authors:  J H GADDUM; C O HEBB; A SILVER; A A SWAN
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1953

Review 4.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

5.  Uptake and disposition of aldrin and dieldrin by isolated perfused rabbit lung.

Authors:  H M Mehendale; E A El-Bassiouni
Journal:  Drug Metab Dispos       Date:  1975 Nov-Dec       Impact factor: 3.922

6.  Properties of benzpyrene hydroxylase in the liver, intestinal mucosa and adrenal of untreated and 3-methylcholanthrene-treated rats.

Authors:  N G Zampaglione; G J Mannering
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

7.  Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds.

Authors:  G Aberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1972

8.  The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.

Authors:  R A Branch; A S Nies; D G Shand
Journal:  Drug Metab Dispos       Date:  1973 Sep-Oct       Impact factor: 3.922

9.  Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.

Authors:  A Hayes; R G Cooper
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

10.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

View more
  13 in total

1.  Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration and measurement.

Authors:  R Mehvar
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

2.  Lidocaine increases lung uptake of propranolol.

Authors:  J A Pang; T R Williams; J P Blackburn; D W Holt; D M Geddes
Journal:  Lung       Date:  1986       Impact factor: 2.584

3.  Feasibility of route extrapolation in risk assessment.

Authors:  W E Pepelko
Journal:  Br J Ind Med       Date:  1987-10

4.  Uptake, distribution, metabolism, and elimination of styrene in man. A comparison between single exposure and co-exposure with acetone.

Authors:  E Wigaeus; A Löf; M B Nordqvist
Journal:  Br J Ind Med       Date:  1984-11

Review 5.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  Pulmonary disposition of pethidine in postoperative patients.

Authors:  M P Persson; P Hartvig; L Wiklund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

7.  Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 8.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Inhalation pharmacokinetics of 1,2-dichloroethane after different dietary pretreatments of male Sprague-Dawley rats.

Authors:  O J Igwe; S S Que Hee; W D Wagner
Journal:  Arch Toxicol       Date:  1986-10       Impact factor: 5.153

10.  Effect of halothane on metabolism of 5-hydroxytryptamine by rat lungs perfused in situ.

Authors:  C A Watkins; S A Wartell; D E Rannels
Journal:  Biochem J       Date:  1983-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.